Influence of hepatic impairment on pharmacokinetics of the human GLP‐1 analogue, liraglutide
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Liraglutide is a novel human GLP‐1 analogue approved for treatment of type 2 diabetes mellitus. Since there is a high prevalence of co‐morbid hepatic impairment in this population it is of clinical importance to establish whether the pharmacokinetics of liraglutide are affected by hepatic impairment. WHAT THIS STUDY ADDS • This study shows that hepatic impairment does not increase liraglutide exposure. Rather, total exposure tends to decrease with increasing degree of hepatic impairment. AIMS: To compare the pharmacokinetics (PK) of a single‐dose of liraglutide in subjects with hepatic impairment. METHODS: This parallel group, open label trial involved four groups of six subjects with healthy, mild, moderate and severe hepatic impairment, respectively. Each subject received 0.75 mg of liraglutide (s.c., thigh), and blood samples were taken over 72 h for PK assessment. Standard laboratory and safety data were collected. The primary endpoint was area under the plasma liraglutide concentration–time curve from time zero to infinity (AUC(0,∞)). RESULTS: Exposure to liraglutide was not increased by hepatic impairment. On the contrary, mean AUC(0,∞) was highest for healthy subjects and lowest for subjects with severe hepatic impairment (severe/healthy: 0.56, with 90% CI 0.39, 0.81) and equivalence in this parameter across groups was not demonstrated. Cmax also tended to decrease with hepatic impairment (severe/healthy: 0.71, with 90% CI 0.52, 0.97), but tmax was similar across groups (11.3–13.2 h). There were no serious adverse events, hypoglycaemic episodes or clinically significant changes in laboratory parameters and liraglutide was considered well tolerated. CONCLUSIONS: This study indicated no safety concerns regarding use of liraglutide in patients with hepatic impairment. Exposure to liraglutide was not increased by impaired liver function; rather, the results suggest a decreased exposure with increasing degree of hepatic impairment. However, data are not conclusive to suggest a dose increase of liraglutide. Thus, the results indicate that patients with type 2 diabetes mellitus and hepatic impairment can use standard treatment regimens of liraglutide. There is, however, currently limited clinical experience with liraglutide in patients with hepatic impairment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 5×
“As noted above, native GLP-1 is rapidly metabolized by DPP-IV, which is widely expressed and can be found in multiple tissues and cell types, as well as in the circulation [5].”
InfluentialAgersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510 · cited 3×
“The bioanalysis of liraglutide in plasma was performed using a validated enzyme-linked immunosorbent assay (ELISA) [16] by Capio Diagnostik a.s., Copenhagen, Denmark.”
InfluentialSelf-citationDegn, K. B., Juhl, C. B., Sturis, J., Jakobsen, G., Brock, B., Chandramouli, V., Rungby, J., Landau, B. R., & Schmitz, O. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1187 · Cited by 427
Obesity-related derangements in metabolic regulation
Muoio, D. M., & Newgard, C. B. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142512 · Cited by 345 · cited 1×
“Also GLP-1 decreases gastric emptying rate and appetite [5, 7], properties that are therapeutically desirable given the association of type 2 diabetes mellitus with obesity, and the association of obesity with insulin resistance [8,9].”
Relationship of Metabolic Risk Factors and Development of Cardiovascular Disease and Diabetes
Haffner, S. M. (2006) · Obesity · doi:10.1038/oby.2006.291 · Cited by 200 · cited 1×
“Also GLP-1 decreases gastric emptying rate and appetite [5, 7], properties that are therapeutically desirable given the association of type 2 diabetes mellitus with obesity, and the association of obesity with insulin resistance [8,9].”
Cited by
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Nauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429
“Limited data exist regarding the use of GLP-1RAs in patients with hepatic functional impairment [62,63].”
Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Jacobsen, L. V., Flint, A., Olsen, A. K., & Ingwersen, S. H. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0343-6 · Cited by 217
“2010;70:807–14 [38] Clinical PK/PD of Liraglutide in Type 2 DM 663”
BackgroundSelf-citationAn evaluation of liraglutide including its efficacy and safety for the treatment of obesity
Lin, C.-H., Shao, L., Zhang, Y.-M., Tu, Y.-J., Zhang, Y., Tomlinson, B., Chan, P., & Liu, Z. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1695779 · Cited by 65
Liraglutide: clinical pharmacology and considerations for therapy
Sisson, E. M. (2011) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.9.896 · Cited by 49
“The AUC of liraglutide tended to decrease with increasing severity of hepatic impairment.(44) Comparisons of AUC ratios between patients with normal renal function and those with severe renal impairment or requiring dialysis did not show equivalence (AUCsevere:AUCnormal ratio 0.”
Background
Metadata
- Authors
- Flint, A., Nazzal, K., Jagielski, P., Hindsberger, C., & Zdravkovic, M.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2010-11-11
- Volume
- 70
- Issue
- 6
- Pages
- 807-814
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W1485586005
- Cited by
- 80
- References
- 5
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Influence of hepatic impairment on pharmacokinetics of the human GLP‐1 analogue, liraglutide. https://app.cochat.ai/papers/10.1111/j.1365-2125.2010.03762.x
- The paper
- Flint, A., Nazzal, K., Jagielski, P., Hindsberger, C., & Zdravkovic, M. (2010). Influence of hepatic impairment on pharmacokinetics of the human GLP‐1 analogue, liraglutide. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2010.03762.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.